MA52924A - Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule - Google Patents

Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule

Info

Publication number
MA52924A
MA52924A MA052924A MA52924A MA52924A MA 52924 A MA52924 A MA 52924A MA 052924 A MA052924 A MA 052924A MA 52924 A MA52924 A MA 52924A MA 52924 A MA52924 A MA 52924A
Authority
MA
Morocco
Prior art keywords
combinations
topical formulations
formulations including
adhesion proteins
mold adhesion
Prior art date
Application number
MA052924A
Other languages
English (en)
Inventor
Ming Gu
Bengt Ingemar Samuelsson
Original Assignee
Jiangyin Mucocare Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangyin Mucocare Pharmaceutical Co Ltd filed Critical Jiangyin Mucocare Pharmaceutical Co Ltd
Publication of MA52924A publication Critical patent/MA52924A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MA052924A 2017-07-05 2018-07-04 Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule MA52924A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017091819 2017-07-05
CN2018087058 2018-05-16

Publications (1)

Publication Number Publication Date
MA52924A true MA52924A (fr) 2021-04-28

Family

ID=64949737

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052924A MA52924A (fr) 2017-07-05 2018-07-04 Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule

Country Status (13)

Country Link
US (3) US11672792B2 (fr)
EP (1) EP3648767A4 (fr)
JP (1) JP7288404B2 (fr)
KR (1) KR102785243B1 (fr)
CN (3) CN113491696A (fr)
AU (1) AU2018295944B2 (fr)
CA (1) CA3068818A1 (fr)
MA (1) MA52924A (fr)
MX (1) MX2020000029A (fr)
MY (1) MY201703A (fr)
SG (1) SG11201911841PA (fr)
TW (1) TWI874298B (fr)
WO (1) WO2019007356A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491696A (zh) * 2017-07-05 2021-10-12 江阴优培尔康药业有限公司 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
MX2021002657A (es) * 2018-09-14 2021-07-21 Jiangyin Usun Pharmaceutical Co Ltd Nuevos conjugados de montelukast y péptidos.
CN113613657A (zh) * 2019-01-10 2021-11-05 江阴优培尔康药业有限公司 含有白三烯受体拮抗剂的新型配制品
CN114375298A (zh) * 2019-09-14 2022-04-19 江阴贝瑞森制药有限公司 新肽
TWI913236B (zh) * 2019-12-02 2026-02-01 大陸商江陰貝瑞森生化技術有限公司 新多功能寡肽
KR20220117256A (ko) * 2019-12-02 2022-08-23 엔리티사 (상하이) 파마슈티컬 컴퍼니 리미티드 펩타이드 및 염증 치료에서의 이의 용도
US12233055B2 (en) 2020-02-03 2025-02-25 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
JP7314421B2 (ja) 2020-02-03 2023-07-25 タロー・ファーマシューティカル・インダストリーズ・リミテッド 局所用モンテルカスト製剤
WO2022078772A1 (fr) 2020-10-13 2022-04-21 Diomed Developments Ltd. Formulations de gel contenant du montélukast
CN114588267A (zh) * 2020-12-04 2022-06-07 江苏恒瑞医药股份有限公司 一种含酰胺类局部麻醉药的药物组合物
WO2022193186A1 (fr) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. Nouveaux agents diagnostiques et thérapeutiques
WO2022193185A1 (fr) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. Nouveaux conjugués
EP4380569A4 (fr) * 2021-08-06 2025-07-02 Enlitisa Shanghai Pharmaceutical Co Ltd Nouveau traitement du trouble de l'immunodéficience
CN116421547A (zh) * 2023-03-09 2023-07-14 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE279185T1 (de) * 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
US20030207932A1 (en) * 2002-05-03 2003-11-06 Morris Mann Compositions that prevent post-traumatic hyperpigmentation and methods related thereto
DK1651161T3 (da) * 2003-08-07 2012-01-30 Healor Ltd Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
US6987170B1 (en) * 2004-08-09 2006-01-17 Battelle Energy Alliance, Llc Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis
WO2007126865A2 (fr) * 2006-03-30 2007-11-08 Patrin Pharma Administration nasale d'antagonistes de leukotriènes
CN1961867A (zh) * 2006-11-16 2007-05-16 徐英权 孟鲁司特钠的颗粒剂型
WO2008105803A1 (fr) 2007-02-26 2008-09-04 Larry Schlesinger Formulations topiques contenant un antagoniste du récepteur de leucotriène et utilisations associées
WO2008106081A1 (fr) * 2007-02-26 2008-09-04 Larry Schlesinger Formulations topiques contenant un antagoniste récepteur d'un leucotriène et leurs utilisations traiter ou prévenir la contracture capsulaire, la formation de cicatrice ou l'hyperpigmentation
WO2009137555A1 (fr) 2008-05-06 2009-11-12 Schlesinger S Larry Formulations topiques et injectables comportant un antagoniste des récepteurs des leucotriènes et leurs utilisations
CA2653011A1 (fr) * 2008-12-03 2010-06-03 Apotex Technologies Inc Appareil et procede d'emballage et de distribution de produits pharmaceutiques
GB0915319D0 (en) * 2009-09-03 2009-10-07 Sharma Anant Combination medicament
CN101773503A (zh) * 2010-01-12 2010-07-14 北京华禧联合科技发展有限公司 一种白三烯拮抗剂和抗组胺药组合物
MX352824B (es) 2010-06-16 2017-12-11 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
CN102895661A (zh) * 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
CN104168892B (zh) 2011-12-26 2017-06-30 Sk化学公司 用于口腔施用的含有孟鲁司特或其可药用盐的膜
CN103239450B (zh) 2012-02-07 2014-11-26 齐鲁制药有限公司 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法
AU2014249531B2 (en) * 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CN103655497B (zh) * 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
CN106573048B (zh) * 2014-08-04 2021-11-09 日东电工株式会社 体液免疫诱导促进用组合物和疫苗药物组合物
CN105769825A (zh) 2014-12-24 2016-07-20 广州朗圣药业有限公司 一种孟鲁司特钠的口腔膜剂及其制备方法
CN105878215A (zh) 2014-12-31 2016-08-24 天津康鸿医药科技发展有限公司 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途
WO2016148455A2 (fr) * 2015-03-13 2016-09-22 경희대학교 산학협력단 Procédé d'amélioration de la biodisponibilité du montélukast
CN104784157B (zh) 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂
AU2015402832B2 (en) * 2015-07-20 2022-06-02 Jiangyin Bengt I. Samuelsson Institute Of Life Science Co., Ltd. Mussel adhesive protein product and applications thereof in suppression of skin inflammations
WO2017011983A1 (fr) * 2015-07-20 2017-01-26 江阴市本特塞缪森生命科学研究院有限公司 Protéine de moule à action adhésive indiquée pour la protection cutanée et de l'appendice cutané
EP3419676B1 (fr) * 2016-02-22 2022-08-31 Board of Regents, The University of Texas System Compositions antimicrobiennes et leurs utilisations
US10548837B1 (en) 2016-05-04 2020-02-04 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis
CN113491696A (zh) * 2017-07-05 2021-10-12 江阴优培尔康药业有限公司 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
MX2021002657A (es) * 2018-09-14 2021-07-21 Jiangyin Usun Pharmaceutical Co Ltd Nuevos conjugados de montelukast y péptidos.
CN113613657A (zh) * 2019-01-10 2021-11-05 江阴优培尔康药业有限公司 含有白三烯受体拮抗剂的新型配制品

Also Published As

Publication number Publication date
EP3648767A4 (fr) 2021-04-28
MY201703A (en) 2024-03-13
CN115300508A (zh) 2022-11-08
CN110312513B (zh) 2022-07-08
EP3648767A1 (fr) 2020-05-13
CN113491696A (zh) 2021-10-12
AU2018295944B2 (en) 2023-12-14
TW201919633A (zh) 2019-06-01
AU2018295944A1 (en) 2020-02-20
JP2020527134A (ja) 2020-09-03
KR20200039677A (ko) 2020-04-16
US20210145819A1 (en) 2021-05-20
JP7288404B2 (ja) 2023-06-07
CA3068818A1 (fr) 2019-01-10
US20230404992A1 (en) 2023-12-21
SG11201911841PA (en) 2020-01-30
KR102785243B1 (ko) 2025-03-26
US20250302818A1 (en) 2025-10-02
MX2020000029A (es) 2020-08-06
US11672792B2 (en) 2023-06-13
TWI874298B (zh) 2025-03-01
WO2019007356A1 (fr) 2019-01-10
CN110312513A (zh) 2019-10-08

Similar Documents

Publication Publication Date Title
EP3648767A4 (fr) Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule
EP3713530A4 (fr) Composition ophtalmique et dispositif d'administration associé
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
MA49043A (fr) Formulation stable d'anticorps
EP3813431C0 (fr) Traitement de fonction de réseau dans le contexte de la mobilité de fonction inter-gestion
EP3633034A4 (fr) PROTÉINE Cas9 MODIFIÉE, ET APPLICATION ASSOCIÉE
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
EP3871532C0 (fr) Boîtier et aspirateur d'arôme le comprenant
EP3307321A4 (fr) Plate-forme d'anticorps multi-spécifiques et procédés associés
MA54052A (fr) Formulation d'anticorps
EP3399033A4 (fr) Marqueur peptidique et protéine marquée comprenant celui-ci
EP3685828A4 (fr) Composition pharmaceutique ophtalmique, trousse ophtalmique et application pharmaceutique associée
SG11202101227TA (en) Novel crispr-associated protein and use thereof
EP3489295A4 (fr) Objet moulé résistant au feu et article moulé comprenant l'objet moulé résistant au feu
EP3374381A4 (fr) Épitopes dans la région centrale de la bêta-amyloïde et anticorps conformationnels sélectifs associés
EP3466452A4 (fr) Module de libération d'arôme et récipient de libération d'arôme comprenant ce dernier
EP3741376A4 (fr) Probiotiques pour inhiber et prévenir l'évolution de maladies rénales et compositions pour inhiber et prévenir l'évolution de maladies rénales les comprenant
EP3611668C0 (fr) Capteurs d'humidité
EP3401364A4 (fr) Modificateur d'asphalte et composition d'asphalte le comprenant
EP3483149A4 (fr) Dérivé de benzo[d]thiazole ou sel de celui-ci et composition pharmaceutique le comprenant
EP3780296A4 (fr) Terminal d'affichage monté sur véhicule et véhicule
EP3601572A4 (fr) Construction d'expression de protéine et procédés associés
EP3813797A4 (fr) Formulation de tiotropium et inhalateur
FR3037094B1 (fr) Chassis de dormant et/ou d'ouvrant
MA50156A (fr) Variants d'anticorps